<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Dbv Technologies S.a. — News on 6ix</title>
<link>https://6ix.com/company/dbv-technologies-sa</link>
<description>Latest news and press releases for Dbv Technologies S.a. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/dbv-technologies-sa" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836171678dffbe2df13d656.webp</url>
<title>Dbv Technologies S.a.</title>
<link>https://6ix.com/company/dbv-technologies-sa</link>
</image>
<item>
<title>Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/information-regarding-the-total-number-of-voting-rights-and-total-number-of-shares-of-the-company-as-of-march-31-2026</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/information-regarding-the-total-number-of-voting-rights-and-total-number-of-shares-of-the-company-as-of-march-31-2026</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 (Article 223-16 of the General</description>
</item>
<item>
<title>DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-announces-filing-of-2025-annual-report-on-form-10-k-and-universal-registration-document</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-announces-filing-of-2025-annual-report-on-form-10-k-and-universal-registration-document</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies</description>
</item>
<item>
<title>DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-to-join-cac-mid-60-and-sbf-120-indices-following-euronext-paris-annual-review-1</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-to-join-cac-mid-60-and-sbf-120-indices-following-euronext-paris-annual-review-1</guid>
<pubDate>Tue, 24 Mar 2026 20:30:00 GMT</pubDate>
<description>Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that following the annual review of the Euronext Paris indices on March 12, 2026, the Scientific Council of the Indices has admitted DBV to the CAC Mid 60 and SBF 120 Indices. The c</description>
</item>
<item>
<title>DBV Technologies to Participate in Upcoming March Investor Conferences</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-to-participate-in-upcoming-march-investor-conferences-70</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-to-participate-in-upcoming-march-investor-conferences-70</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>Châtillon, France, March 4, 2026 DBV Technologies to Participate in Upcoming March Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –</description>
</item>
<item>
<title>Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/information-regarding-the-total-number-of-voting-rights-and-total-number-of-shares-of-the-company-as-of-february-28-2026</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/information-regarding-the-total-number-of-voting-rights-and-total-number-of-shares-of-the-company-as-of-february-28-2026</guid>
<pubDate>Tue, 03 Mar 2026 21:30:00 GMT</pubDate>
<description>Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights02/28/2026 278,352,082 Total gross of voting rights: 278,352,082 Total net* of voting rights: 278,236,200 * Net total = total number of voting rights attached to shares – shares withou</description>
</item>
<item>
<title>DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-highlights-additional-data-from-successful-phase-3-vitesse-study-at-the-aaaai-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-highlights-additional-data-from-successful-phase-3-vitesse-study-at-the-aaaai-2026-annual-meeting</guid>
<pubDate>Sat, 28 Feb 2026 19:25:00 GMT</pubDate>
<description>Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo groupApproximately 60% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose by at least two doses at month 12, compared to 23% in the placebo group24% of childre</description>
</item>
<item>
<title>DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-present-additional-data-213000601</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-present-additional-data-213000601</guid>
<pubDate>Tue, 10 Feb 2026 21:30:00 GMT</pubDate>
<description>Châtillon, France, February 10, 2026 DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the company will present additional data for the VIASKIN® Peanut Patch in children ages 4-7 years from th</description>
</item>
<item>
<title>DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-participate-guggenheim-securities-213000313</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-participate-guggenheim-securities-213000313</guid>
<pubDate>Mon, 09 Feb 2026 21:30:00 GMT</pubDate>
<description>Châtillon, France, February 9, 2025 DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit which is being held February 11-12, 2026 in New York, NY. Mr. Tassé’s presenta</description>
</item>
<item>
<title>Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/information-regarding-total-number-voting-213000529</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/information-regarding-total-number-voting-213000529</guid>
<pubDate>Thu, 05 Feb 2026 21:30:00 GMT</pubDate>
<description>Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights01/31/2026 274,852,082 Total gross of voting rights: 274,852,082 Total net* of voting rights: 274,792,237 * Net total = total number of voting rights attached to shares – shares without</description>
</item>
<item>
<title>DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-announces-166-7-231100771</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-announces-166-7-231100771</guid>
<pubDate>Fri, 16 Jan 2026 23:11:00 GMT</pubDate>
<description>Châtillon, France, January 16, 2026 DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing The Company is sufficiently funded to support operations and commercial preparedness, including infrastructure buildup, to launch the VIASKIN® Peanut patch in children 4 to 7 years old in the U.S., if approved. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Com</description>
</item>
<item>
<title>Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/information-regarding-total-number-voting-210000637</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/information-regarding-total-number-voting-210000637</guid>
<pubDate>Mon, 12 Jan 2026 21:00:00 GMT</pubDate>
<description>Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Notice:This document supersedes and replaces the information previously published on January 5, 2026, to account for the earlier exercise of various securities instruments, in connection with the Company’s employee stock ownership plans and warrants from a previous financing transaction. Market</description>
</item>
<item>
<title>Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/half-report-dbv-technologies-liquidity-210000056</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/half-report-dbv-technologies-liquidity-210000056</guid>
<pubDate>Wed, 07 Jan 2026 21:00:00 GMT</pubDate>
<description>AMF Regulated InformationChâtillon, France, January 7, 2026 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2025: 74,580 DBV Techn</description>
</item>
<item>
<title>Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/information-regarding-the-total-number-of-voting-rights-and-total-number-of-shares-of-the-company-as-of-december-31-2025</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/information-regarding-the-total-number-of-voting-rights-and-total-number-of-shares-of-the-company-as-of-december-31-2025</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025 (Article 223-16 of the General</description>
</item>
<item>
<title>DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-announces-positive-topline-210500360</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-announces-positive-topline-210500360</guid>
<pubDate>Tue, 16 Dec 2025 21:05:00 GMT</pubDate>
<description>Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% 46.6% of children treated with the VIASKIN® Peanut patch met response criteria at 12 months, compared to 14.8% of children in the plac</description>
</item>
<item>
<title>Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/information-regarding-total-number-voting-210000344</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/information-regarding-total-number-voting-210000344</guid>
<pubDate>Tue, 02 Dec 2025 21:00:00 GMT</pubDate>
<description>Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2025 200,777,718 Total gross of voting rights: 200,777,718 Total net* of voting rights: 200,667,869 * Net total = total number of voting rights attached to shares – shares withou</description>
</item>
<item>
<title>ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/alk-appoints-edward-jordan-as-new-evp-and-head-of-commercial-operations-north-america</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/alk-appoints-edward-jordan-as-new-evp-and-head-of-commercial-operations-north-america</guid>
<pubDate>Mon, 01 Dec 2025 14:35:00 GMT</pubDate>
<description>ALK (ALKB:DC / OMX: ALK B) today announced the appointment of Edward Jordan as new Executive Vice President (EVP) and head of Commercial Operations in North America as per 5 January 2026. Edward Jordan succeeds Søren Niegel who has temporarily assumed the position following the decision, effective 1 October 2025, to elevate ALK’s two key commercial regions, Europe and North America. into the Executive Leadership Team (ELT) to further strengthen the execution of ALK’s Allergy+ strategy. Edward Jo</description>
</item>
<item>
<title>DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-announces-last-patient-045000201</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-announces-last-patient-045000201</guid>
<pubDate>Wed, 12 Nov 2025 04:50:00 GMT</pubDate>
<description>Châtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Company remains on track for VITESSE topline data in Q4 of this year DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the last patient visit has been completed in the Company’s Phase 3 VI</description>
</item>
<item>
<title>DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-participate-guggenheim-2nd-213000652</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-participate-guggenheim-2nd-213000652</guid>
<pubDate>Tue, 04 Nov 2025 21:30:00 GMT</pubDate>
<description>Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, at 2:00 p.m. ET in Boston, Massachusetts. A li</description>
</item>
<item>
<title>DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-appoints-industry-leader-213000649</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/dbv-technologies-appoints-industry-leader-213000649</guid>
<pubDate>Mon, 03 Nov 2025 21:30:00 GMT</pubDate>
<description>Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global</description>
</item>
<item>
<title>Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025</title>
<link>https://6ix.com/company/dbv-technologies-sa/news/information-regarding-total-number-voting-212500704</link>
<guid isPermaLink="true">https://6ix.com/company/dbv-technologies-sa/news/information-regarding-total-number-voting-212500704</guid>
<pubDate>Mon, 03 Nov 2025 21:25:00 GMT</pubDate>
<description>Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 10/31/2025 179,827,919 Total gross of voting rights: 179,827,919 Total net* of voting rights: 179,741,847 * Net total = total number of voting rights attached to shares – shares withou</description>
</item>
</channel>
</rss>